TWI340134B - Cyclohexanecarboxylic acids - Google Patents

Cyclohexanecarboxylic acids

Info

Publication number
TWI340134B
TWI340134B TW093122176A TW93122176A TWI340134B TW I340134 B TWI340134 B TW I340134B TW 093122176 A TW093122176 A TW 093122176A TW 93122176 A TW93122176 A TW 93122176A TW I340134 B TWI340134 B TW I340134B
Authority
TW
Taiwan
Prior art keywords
cyclohexanecarboxylic acids
pyrrolidinylmethoxy
indolylcarbonyl
cyclohexanecarboxylate
vla
Prior art date
Application number
TW093122176A
Other languages
English (en)
Other versions
TW200517374A (en
Inventor
Makoto Ono
Shigeru Noguchi
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co
Publication of TW200517374A publication Critical patent/TW200517374A/zh
Application granted granted Critical
Publication of TWI340134B publication Critical patent/TWI340134B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW093122176A 2003-07-24 2004-07-23 Cyclohexanecarboxylic acids TWI340134B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003201062 2003-07-24

Publications (2)

Publication Number Publication Date
TW200517374A TW200517374A (en) 2005-06-01
TWI340134B true TWI340134B (en) 2011-04-11

Family

ID=34100472

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093122176A TWI340134B (en) 2003-07-24 2004-07-23 Cyclohexanecarboxylic acids

Country Status (13)

Country Link
US (2) US7691894B2 (zh)
EP (1) EP1650205B1 (zh)
JP (1) JP4676884B2 (zh)
KR (1) KR101051842B1 (zh)
CN (1) CN1826336B (zh)
AT (1) ATE555106T1 (zh)
CA (2) CA2770493A1 (zh)
ES (1) ES2382806T3 (zh)
HK (1) HK1091484A1 (zh)
IL (1) IL172443A0 (zh)
MX (1) MXPA06000850A (zh)
TW (1) TWI340134B (zh)
WO (1) WO2005009992A1 (zh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2770493A1 (en) * 2003-07-24 2005-02-03 Daiichi Pharmaceutical Co., Ltd. Cyclohexanecarboxylic acid compound
WO2007069635A1 (ja) * 2005-12-13 2007-06-21 Daiichi Sankyo Company, Limited Ｖｌａ－４阻害薬
US20110160644A1 (en) * 2007-08-17 2011-06-30 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems, devices, and methods including catheters configured to release ultraviolet energy absorbing agents
US8460229B2 (en) 2007-08-17 2013-06-11 The Invention Science Fund I, Llc Systems, devices, and methods including catheters having components that are actively controllable between transmissive and reflective states
US8162924B2 (en) 2007-08-17 2012-04-24 The Invention Science Fund I, Llc System, devices, and methods including actively-controllable superoxide water generating systems
US8366652B2 (en) * 2007-08-17 2013-02-05 The Invention Science Fund I, Llc Systems, devices, and methods including infection-fighting and monitoring shunts
US8702640B2 (en) * 2007-08-17 2014-04-22 The Invention Science Fund I, Llc System, devices, and methods including catheters configured to monitor and inhibit biofilm formation
US8734718B2 (en) * 2007-08-17 2014-05-27 The Invention Science Fund I, Llc Systems, devices, and methods including catheters having an actively controllable therapeutic agent delivery component
US8753304B2 (en) * 2007-08-17 2014-06-17 The Invention Science Fund I, Llc Systems, devices, and methods including catheters having acoustically actuatable waveguide components for delivering a sterilizing stimulus to a region proximate a surface of the catheter
US8647292B2 (en) * 2007-08-17 2014-02-11 The Invention Science Fund I, Llc Systems, devices, and methods including catheters having components that are actively controllable between two or more wettability states
US20090163977A1 (en) * 2007-08-17 2009-06-25 Searete Llc, A Limited Liability Corporation Of The State Of Delaware System, devices, and methods including sterilizing excitation delivery implants with cryptographic logic components
US20090048648A1 (en) * 2007-08-17 2009-02-19 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Self-sterilizing device
US20090177254A1 (en) * 2007-08-17 2009-07-09 Searete Llc, A Limited Liability Of The State Of The State Of Delaware System, devices, and methods including actively-controllable electrostatic and electromagnetic sterilizing excitation delivery system
US8706211B2 (en) * 2007-08-17 2014-04-22 The Invention Science Fund I, Llc Systems, devices, and methods including catheters having self-cleaning surfaces
US20090163964A1 (en) * 2007-08-17 2009-06-25 Searete Llc, A Limited Liability Corporation Of The State Of Delaware System, devices, and methods including sterilizing excitation delivery implants with general controllers and onboard power
EP2384168B1 (en) * 2008-12-04 2014-10-08 Searete LLC Actively-controllable sterilizing excitation delivery implants
US20110295089A1 (en) 2008-12-04 2011-12-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems, devices, and methods including implantable devices with anti-microbial properties
US8585627B2 (en) * 2008-12-04 2013-11-19 The Invention Science Fund I, Llc Systems, devices, and methods including catheters configured to monitor biofilm formation having biofilm spectral information configured as a data structure
US20110152751A1 (en) * 2008-12-04 2011-06-23 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems, devices, and methods including catheters having UV-Energy emitting coatings
US11224600B2 (en) 2018-10-30 2022-01-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
AU2019373240B2 (en) 2018-10-30 2023-04-20 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
CA3115830C (en) 2018-10-30 2023-09-12 Gilead Sciences, Inc. Compounds for inhibition of .alpha.4.beta.7 integrin
JP7214882B2 (ja) 2018-10-30 2023-01-30 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリン阻害剤としてのイミダゾピリジン誘導体
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
DE2500157C2 (de) 1975-01-03 1983-09-15 Hoechst Ag, 6230 Frankfurt N-Acyl-4-(2-aminoäthyl)-benzoesäuren, deren Salze und Ester, Verfahren zu deren Herstellung und deren Verwendung
DE2706977A1 (de) 1977-02-18 1978-08-24 Hoechst Ag Benzoesaeuren und deren derivate sowie verfahren zu ihrer herstellung
DE3063878D1 (en) 1979-07-13 1983-07-28 Thomae Gmbh Dr K Derivatives of carboxylic acids, their preparation and medicaments containing them
JPS60181081A (ja) 1984-02-29 1985-09-14 Kaken Pharmaceut Co Ltd 新規ビスベンゾフラニルケトン誘導体
JPH04112868A (ja) 1990-09-03 1992-04-14 Otsuka Pharmaceut Co Ltd 置換ヘテロ環を有するフェニルカルボン酸誘導体
JPH0543574A (ja) 1991-08-13 1993-02-23 Wakamoto Pharmaceut Co Ltd ヘテロ環置換テトラゾール−１−酢酸誘導体
FR2694295B1 (fr) 1992-07-28 1994-09-02 Adir Nouveaux peptides dérivés de trifluoromethylcetones, leur procéde de préparation et les compositions pharmaceutiques qui les contiennent.
ES2103181B1 (es) 1994-08-01 1998-04-01 Menarini Lab Amidas naftalenicas con accion antagonista de los leucotrienos.
GB9408936D0 (en) 1994-05-05 1994-06-22 Cancer Res Inst Anti-cancer compounds
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
WO1997002024A1 (en) 1995-06-30 1997-01-23 Smithkline Beecham Corporation Use of stat 5 sh2 domain specific compounds to enhance erythropoiesis
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
AU3738597A (en) 1996-07-25 1998-02-20 Biogen, Inc. Molecular model for vla-4 inhibitors
CA2264020A1 (en) 1996-08-26 1998-03-05 Jean Bemis Inhibitors of phospholipase enzymes
DE19647381A1 (de) 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
HUP0000492A3 (en) 1996-11-22 2000-06-28 Lilly Co Eli N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
US6117901A (en) 1996-11-22 2000-09-12 Athena Neurosciences, Inc. N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for use
ATE289991T1 (de) 1997-12-23 2005-03-15 Aventis Pharma Ltd Substituierte beta-alaninen
CN1298404A (zh) 1998-02-25 2001-06-06 遗传研究所有限公司 磷脂酶a2的抑制剂
SI1082302T1 (en) 1998-05-28 2004-06-30 Biogen, Inc. A vla-4 inhibitor: omepupa-v
CN1311771A (zh) 1998-06-08 2001-09-05 味之素株式会社 苯甲脒衍生物
TR200003848T2 (tr) 1998-06-30 2001-06-21 Pfizer Products Inc. VLA-4'e bağlı hücre bağlanmasının peptidil olmayan önleyicileri.
GB9916374D0 (en) 1998-07-23 1999-09-15 Zeneca Ltd Chemical compounds
AU5052199A (en) 1998-07-23 2000-02-14 Astrazeneca Ab Chemical compounds
DE69934238T2 (de) 1998-08-26 2007-06-21 Aventis Pharma Ltd., West Malling Azabicyclo-verbindungen welche die inhibition der zell adhesion modulieren
GB9821199D0 (en) 1998-09-30 1998-11-25 Glaxo Group Ltd Chemical compounds
US6429132B1 (en) 1998-12-23 2002-08-06 Aurora Systems, Inc. Combination CMP-etch method for forming a thin planar layer over the surface of a device
US6207700B1 (en) 1999-01-07 2001-03-27 Vanderbilt University Amide derivatives for antiangiogenic and/or antitumorigenic use
DK1153017T3 (da) 1999-02-16 2006-07-17 Aventis Pharma Ltd Bicykliske forbindelser og deres anvendelse som integrinreceptorligander
JP2000344666A (ja) 1999-04-01 2000-12-12 Sankyo Co Ltd 糖及び脂質代謝改善剤
SK14372001A3 (sk) 1999-04-12 2002-06-04 Aventis Pharma Limited Substituované bicyklické heteroarylové zlúčeniny ako antagonisty integrínu a farmaceutický prostriedok, ktorý ich obsahuje
JP2002543129A (ja) 1999-05-05 2002-12-17 メルク エンド カムパニー インコーポレーテッド 抗微生物剤としての新規なプロリン類
EP1177181B1 (en) 1999-05-05 2009-01-28 Aventis Pharma Limited Substituted bicyclic compounds
AU4591500A (en) 1999-05-05 2000-11-21 Aventis Pharma Limited Substituted pyrrolidines
IL146288A0 (en) 1999-06-30 2002-07-25 Daiichi Seiyaku Co Vla-4 inhibitor compounds
KR100720907B1 (ko) 1999-08-13 2007-05-25 바이오겐 아이덱 엠에이 인코포레이티드 세포 유착 억제제
EP1263726B1 (en) 1999-11-10 2007-09-26 Sanofi-Aventis Deutschland GmbH N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor xa
JP2003519697A (ja) 1999-12-28 2003-06-24 ファイザー・プロダクツ・インク 炎症性疾患、自己免疫疾患および呼吸器疾患の処置に有用な非ペプチド系のｖｌａ−４依存性細胞結合阻害薬
GB0001346D0 (en) 2000-01-21 2000-03-08 Astrazeneca Uk Ltd Chemical compounds
DE10006453A1 (de) 2000-02-14 2001-08-16 Bayer Ag Piperidylcarbonsäuren als Integrinantagonisten
GB0004686D0 (en) 2000-02-28 2000-04-19 Aventis Pharma Ltd Chemical compounds
AU2001235806A1 (en) 2000-03-01 2001-09-12 Aventis Pharma Limited 2,3-dihydro-1h-indolinyl-alkanoic acids as cell adhesion inhibitors
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
CN1620433A (zh) 2000-07-19 2005-05-25 霍夫曼-拉罗奇有限公司 作为内皮肽转化酶抑制剂的吡咯烷衍生物
EP1346982B1 (en) * 2000-12-28 2011-09-14 Daiichi Pharmaceutical Co., Ltd. Vla-4 inhibitors
GB2377933A (en) 2001-07-06 2003-01-29 Bayer Ag Succinic acid derivatives useful as integrin antagonists
EP1623975A4 (en) * 2003-05-09 2008-07-02 Daiichi Seiyaku Co PROCESS FOR PREPARING A PYRROLIDINE DERIVATIVE
CA2770493A1 (en) * 2003-07-24 2005-02-03 Daiichi Pharmaceutical Co., Ltd. Cyclohexanecarboxylic acid compound

Also Published As

Publication number Publication date
ES2382806T3 (es) 2012-06-13
JP4676884B2 (ja) 2011-04-27
US20070105936A1 (en) 2007-05-10
IL172443A0 (en) 2006-04-10
TW200517374A (en) 2005-06-01
US20100022783A1 (en) 2010-01-28
KR101051842B1 (ko) 2011-07-25
CN1826336B (zh) 2010-06-02
ATE555106T1 (de) 2012-05-15
JPWO2005009992A1 (ja) 2006-09-07
CA2528586A1 (en) 2005-02-03
EP1650205A1 (en) 2006-04-26
US7893279B2 (en) 2011-02-22
EP1650205A4 (en) 2010-04-28
MXPA06000850A (es) 2006-03-30
KR20060037394A (ko) 2006-05-03
CA2770493A1 (en) 2005-02-03
HK1091484A1 (en) 2007-01-19
CN1826336A (zh) 2006-08-30
WO2005009992A1 (ja) 2005-02-03
US7691894B2 (en) 2010-04-06
EP1650205B1 (en) 2012-04-25

Similar Documents

Publication Publication Date Title
HK1091484A1 (en) Cyclohexanecarboxylic acid compound
HK1145322A1 (zh)
IL159418A0 (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
YU41801A (sh) Derivati fenilglicina
GB0124627D0 (en) Novel compounds
DE60141940D1 (de) Rückgewinnung von Kohlendioxid bei hohem Druck
GB9801690D0 (en) Therapeutic agents
RS93604A (en) Substituted phenylacetamides and their use as glucokinase activators
HN1999000155A (es) 4-carboxiamino-2-metil-1,2,3,4-tetrahidroquinolinas
MY136789A (en) Metalloproteinase inhibitors
AU148080S (en) Spray pump head
JO2410B1 (en) 6. Replaced pyrido-pyrimidines
HU0201152D0 (zh)
JO2369B1 (en) New cyclohexyl sulfonate
BR0212772A (pt) Processo para a preparação de repaglinida
ATE265003T1 (de) Befestigungsklammer für weiches material
CY1106738T1 (el) Διεργασια και ενδιαμεσα για την παρασκευη αναστολεων ρετροϊικης πρωτεασης
ATE427934T1 (de) Nicht-peptidische brs-3-agonisten
DK1223350T3 (da) Klemholder til pladeformede elementer
RS52014B (sr) Nova so benzoilgvanidina
DE60111864D1 (de) Sägebügel für handbügelsäge
ATE401487T1 (de) Dichtungsprofil
AR033305A1 (es) Procedimiento para preparar un aminoacido biciclico
RS20050063A (en) Pyrrolidine derivatives as tryptase inhibitors
MXPA04003478A (es) Sintesis de (4-bromofenil)(4-piperidil)metanona-(z)-o-etiloxima y sales.

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees